
Michael Jeltsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8565293/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. Journal of Cell Biology, 2003, 161, 1163-1177.	2.3	2,483
2	Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunology, 2004, 5, 74-80.	7.0	1,208
3	Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice. Science, 1997, 276, 1423-1425.	6.0	1,160
4	Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 548-553.	3.3	1,078
5	Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO Journal, 2001, 20, 672-682.	3.5	808
6	Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO Journal, 1997, 16, 3898-3911.	3.5	669
7	Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO Journal, 2001, 20, 1223-1231.	3.5	583
8	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	3.9	475
9	Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11709-11714.	3.3	472
10	VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane. Developmental Biology, 1997, 188, 96-109.	0.9	438
11	Vascular Endothelial Cell Growth Factor Receptor 3–Mediated Activation of Lymphatic Endothelium Is Crucial for Tumor Cell Entry and Spread via Lymphatic Vessels. Cancer Research, 2005, 65, 4739-4746.	0.4	361
12	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	3.9	326
13	Functional interaction of VEGF and VEGFâ€Ð with neuropilin receptors. FASEB Journal, 2006, 20, 1462-1472.	0.2	265
14	Adenoviral Expression of Vascular Endothelial Growth Factor-C Induces Lymphangiogenesis in the Skin. Circulation Research, 2001, 88, 623-629.	2.0	197
15	<i>CCBE1</i> Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3–Mediated Vascular Endothelial Growth Factor-C Activation. Circulation, 2014, 129, 1962-1971.	1.6	195
16	Genomic Organization of Human and Mouse Genes for Vascular Endothelial Growth Factor C. Journal of Biological Chemistry, 1997, 272, 25176-25183.	1.6	161
17	Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2425-2430.	3.3	160
18	Current biology of VEGF-B and VEGF-C. Current Opinion in Biotechnology, 1999, 10, 528-538.	3.3	155

MICHAEL JELTSCH

#	Article	IF	CITATIONS
19	Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. , 1998, 177, 439-452.		153
20	Adenoviral VEGFâ \in C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB Journal, 2002, 16, 1041-1049.	0.2	147
21	Receptor Tyrosine Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology, 2013, 5, a009183-a009183.	2.3	135
22	Overexpression of Vascular Endothelial Growth Factor-B in Mouse Heart Alters Cardiac Lipid Metabolism and Induces Myocardial Hypertrophy. Circulation Research, 2008, 103, 1018-1026.	2.0	131
23	Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation, 2010, 122, 1725-1733.	1.6	129
24	Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta. Circulation, 2000, 102, 2262-2268.	1.6	127
25	Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization. Cancer Cell, 2010, 18, 630-640.	7.7	119
26	Vascular endothelial growth factors VEGF-B and VEGF-C. Journal of Cellular Physiology, 1997, 173, 211-215.	2.0	112
27	The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis. Cancer Research, 2008, 68, 4754-4762.	0.4	104
28	Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels. Frontiers in Bioengineering and Biotechnology, 2018, 6, 7.	2.0	102
29	Reevaluation of the Role of VEGF-B Suggests a Restricted Role in the Revascularization of the Ischemic Myocardium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1614-1620.	1.1	99
30	A truncation allele in <i>vascular endothelial growth factor c</i> reveals distinct modes of signaling during lymphatic and vascular development. Development (Cambridge), 2013, 140, 1497-1506.	1.2	98
31	Genesis and pathogenesis of lymphatic vessels. Cell and Tissue Research, 2003, 314, 69-84.	1.5	89
32	Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle. Circulation Research, 2009, 104, 1302-1312.	2.0	89
33	Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12960-12965.	3.3	84
34	Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood, 2011, 117, 1507-1515.	0.6	76
35	Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB Journal, 2003, 17, 2006-2013.	0.2	71
36	Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Scientific Reports, 2017, 7, 4916.	1.6	69

MICHAEL JELTSCH

#	Article	IF	CITATIONS
37	Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis. Circulation, 2013, 127, 424-434.	1.6	53
38	Key molecules in lymphatic development, function, and identification. Annals of Anatomy, 2018, 219, 25-34.	1.0	53
39	The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor–1 Ligands. Science Signaling, 2013, 6, ra52.	1.6	49
40	Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE, 2010, 5, e14109.	1.1	45
41	Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis. American Journal of Pathology, 2012, 181, 1607-1620.	1.9	45
42	Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1421-1429.	2.5	40
43	Functional Dissection of the CCBE1 Protein. Circulation Research, 2015, 116, 1660-1669.	2.0	39
44	VEGF-C protects the integrity of the bone marrow perivascular niche in mice. Blood, 2020, 136, 1871-1883.	0.6	38
45	Ischemia–Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. American Journal of Transplantation, 2016, 16, 1160-1172.	2.6	37
46	Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes and Development, 2010, 24, 875-880.	2.7	36
47	Lymphatic Vessels in Regenerative Medicine and Tissue Engineering. Tissue Engineering - Part B: Reviews, 2016, 22, 395-407.	2.5	35
48	Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circulation Research, 2007, 100, 1468-1475.	2.0	34
49	Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns. Journal of Biological Chemistry, 2006, 281, 12187-12195.	1.6	33
50	KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. ELife, 2019, 8, .	2.8	31
51	Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis. Circulation Research, 2016, 119, 210-221.	2.0	26
52	Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs. Biology, 2021, 10, 167.	1.3	25
53	Factors regulating the substrate specificity of cytosolic phospholipase A 2 -alpha in vitro. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1597-1604.	1.2	15
54	Enhanced Capillary Formation Stimulated by a Chimeric Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor-C Silk Domain Fusion Protein. Circulation Research, 2007, 100, 1460-1467.	2.0	13

MICHAEL JELTSCH

#	Article	IF	CITATIONS
55	Substrate Efflux Propensity Is the Key Determinant of Ca2+-independent Phospholipase A-β (iPLAβ)-mediated Glycerophospholipid Hydrolysis. Journal of Biological Chemistry, 2015, 290, 10093-10103.	1.6	9
56	The TIE Receptor Family. , 2015, , 743-775.		7
57	KLK3 in the Regulation of Angiogenesis—Tumorigenic or Not?. International Journal of Molecular Sciences, 2021, 22, 13545.	1.8	7
58	Investigation on the role of biallelic variants in <i>VEGFâ€C</i> found in a patient affected by Milroyâ€like lymphedema. Molecular Genetics & Genomic Medicine, 2020, 8, e1389.	0.6	6
59	Vascular endothelial growth factors VEGF-B and VEGF-C. , 1997, 173, 211.		3
60	Outside in and brakes off for lymphatic growth. Science Signaling, 2021, 14, .	1.6	2
61	341 VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. Journal of Heart and Lung Transplantation, 2011, 30, S118.	0.3	1
62	VEGF-C adenovirus gene transfer reduces intima formation in rabbits. Atherosclerosis, 2000, 151, 81.	0.4	0